$BIIB Recent Headlines Biogen Idec investors focus on

New Post Public Reply Private Reply Replies (0) Message Board

Jan 31, 2014 at 3:26 PM

$BIIB Recent Headlines

Biogen Idec investors focus on positive, ignore outlook for 2014 2:02 p.m. Jan. 29, 2014 - blogs.marketwatch.com
Biogen profit jumps on MS treatment revenue 7:09 a.m. Jan. 29, 2014 - MarketWatch.com
Stock investors trash market darlings, face Apple, Fed 8:00 a.m. Jan. 26, 2014 - Wallace Witkowski
The market puts a few feathers in its cap 1:58 p.m. Jan. 23, 2014 - The Trading Deck
Speculators turn the heat up to ‘soft boil’ 3:54 p.m. Jan. 16, 2014 - The Trading Deck
GameStop tumbles 20%; Tesla surges on strong sales 4:22 p.m. Jan. 14, 2014 - Ben Eisen
Beam up on Suntory deal; Elliott report lifts Juniper 4:17 p.m. Jan. 13, 2014 - Saumya Vaishampayan
Biogen, Sangamo partner on hemoglobin therapies 9:38 a.m. Jan. 9, 2014 - MarketWatch.com
Earnings boost Micron, drag on Container Store 4:24 p.m. Jan. 8, 2014 - Ben Eisen
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Charting a bullish year-end backdrop 12:28 p.m. Dec. 17, 2013 - Michael Ashbaugh
Charting a bullish year-end backdrop 12:03 p.m. Dec. 17, 2013 - Michael Ashbaugh
Get your portfolio to turn the corner 2:32 p.m. Dec. 10, 2013 - The Trading Deck
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Growth stock players should reduce expectations 1:18 p.m. Nov. 26, 2013 - The Trading Deck
DaVita, Fresenius gain; energy firms slip 4:55 p.m. Nov. 25, 2013 - Ben Eisen
Stocks gain for 7th week; S&P ends above 1,800 4:24 p.m. Nov. 22, 2013 - Polya Lesova
Biogen Idec jumps; Intel, Ross Stores slide 4:23 p.m. Nov. 22, 2013 - Ben Eisen
Biogen surges 13%, best on S&P 500 9:33 a.m. Nov. 22, 2013 - Laura Mandaro
The Four Horsemen send a message 12:46 p.m. Nov. 13, 2013 - The Trading Deck

Biotech Sector Performance January 2014 Strong, but What's Ailing Celgene? 2:12 p.m. Today - TheStreet.com
Zacks Rank #1 Additions for Friday - Tale of the Tape 9:30 a.m. Today - Zacks.com
Facebook Tops 5 Leaders With Rising Profit Estimates 8:00 a.m. Today - Investors Business Daily
Jefferies Says Buy Any Pullback on Top Focus Stocks for Big Gains 7:22 a.m. Today - 247WallSt.com
Biogen Idec Is a Buy Idea 12:09 a.m. Today - Barrons.com
Celgene -2.2% after earnings, NEJM report, while other big biotechs surge 2:44 p.m. Jan. 30, 2014 - Seeking Alpha
Biogen Idec Inc. (BIIB): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Jan. 30, 2014 - Zacks.com
FDA Nod for New Formulation of Teva's Copaxone - Analyst Blog 5:10 p.m. Jan. 29, 2014 - Zacks.com
Biogen's Report Sends Stock Up; Other Biotechs Follow 5:01 p.m. Jan. 29, 2014 - Investors Business Daily
Will Affymetrix (AFFX) Surprise This Earnings Season? - Analyst Blog 4:30 p.m. Jan. 29, 2014 - Zacks.com
Biogen Beats, Tecfidera Continues to Shine - Analyst Blog 1:32 p.m. Jan. 29, 2014 - Zacks.com
Biogen Idec Management Discusses Q4 2013 Results - Earnings Call Transcript 12:50 p.m. Jan. 29, 2014 - Seeking Alpha
Why Caution Is Prevailing in Biotechs Into and After Earnings 11:29 a.m. Jan. 29, 2014 - 247WallSt.com
New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN) 10:44 a.m. Jan. 29, 2014 - benzinga.com
Biogen MS Drug Tecfidera Outperforms; Outlook Light 10:41 a.m. Jan. 29, 2014 - Investors Business Daily
Top Trending Tickers On StockTwits For January 29 8:51 a.m. Jan. 29, 2014 - benzinga.com
An Option On Adoption Of A New Multiple Sclerosis Treatment 8:51 a.m. Jan. 29, 2014 - Seeking Alpha
Biogen profit powers higher on strong sales for MS treatment 8:14 a.m. Jan. 29, 2014 - Seeking Alpha
The Best of the Best Picks of the Credit Suisse Top 50 Stocks 8:09 a.m. Jan. 29, 2014 - 247WallSt.com
Facebook, Biogen, Sands Among Top Big Caps Reporting 7:02 a.m. Jan. 29, 2014 - Investors Business Daily

Biogen Idec Foundation Awards Museum of Science $2.5 Million to Support Hall of Human Life 8:30 a.m. Jan. 30, 2014 - BusinessWire - BZX
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia 1:00 a.m. Jan. 30, 2014 - BusinessWire - BZX
Biogen Idec 2013 Total Revenues Increase 26 Percent to $6.9 Billion 6:30 a.m. Jan. 29, 2014 - BusinessWire - BZX
RBCC Develops Innovations in White-Hot 3D Bioprinting Sector 4:00 a.m. Jan. 27, 2014 - BusinessWire - BZX
RXI Pharmaceuticals Could Benefit from Biotech Industry Dynamics 10:06 a.m. Jan. 24, 2014 - ACCESSWIRE
Critical Alerts For General Electric, SodaStream, Biogen Idec, Linn Energy, and Allscripts Released By InvestorsObserver 9:31 a.m. Jan. 24, 2014 - PR Newswire - PRF
RBCC Moves to the Front Lines of the 3D Bioprinting Revolution 5:00 a.m. Jan. 20, 2014 - BusinessWire - BZX
RBCC Prepares Big Push Into Booming 3D Bioprinting Market 5:00 a.m. Jan. 16, 2014 - BusinessWire - BZX
Biogen Idec to Report Fourth Quarter and Year-End 2013 Financial Results on January 29, 2014 4:01 p.m. Jan. 15, 2014 - BusinessWire - BZX
RBCC Partner Therakine Presents Novel Drug Delivery Technology at Biotech Showcase 5:00 a.m. Jan. 15, 2014 - BusinessWire - BZX
Biogen Idec Announces Availability of FAMPYRA® in Ireland to Treat Walking Impairment in Adults with Multiple Sclerosis 4:00 a.m. Jan. 15, 2014 - BusinessWire - BZX
Leading Life Sciences CEOs Honor Johnson & Johnson Chief Scientific Officer Paul Stoffels with Lifetime Achievement Award at Annual East/West CEO Conference 9:49 a.m. Jan. 14, 2014 - BusinessWire - BZX
ShangPharma Appoints Pharmaceutical Executive Dr. Mitchell Reff Chief Biologics Officer 9:10 a.m. Jan. 13, 2014 - PR Newswire - PRF
RBCC Partner n3D Commercializes New 3D Bioprinting Technology 5:53 a.m. Jan. 13, 2014 - BusinessWire - BZX
Sangamo BioSciences Announces Conference Call And Webcast To Discuss Global Collaboration with Biogen Idec to Develop Treatments for Hemoglobinopathies 7:10 a.m. Jan. 9, 2014 - PR Newswire
Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies 7:00 a.m. Jan. 9, 2014 - PR Newswire
Sunesis Pharmaceuticals Expands Hematology Franchise With Global Licenses to Two Kinase Inhibitor Programs 6:59 a.m. Jan. 9, 2014 - GlobeNewswire
Biogen Idec to Present at the 32nd Annual J.P. Morgan Healthcare Conference 5:29 p.m. Jan. 7, 2014 - BusinessWire
Galectin Therapeutics Receives Patent for Combination Treatment for Liver Fibrosis 12:17 p.m. Jan. 7, 2014 - ACCESSWIRE
Stock Price Movement, Financial Reports Schedules, Conference Participation, Leadership Changes, and Donation - Research Report on Biogen Idec, Forest, PerkinElmer, Techne, and USANA 8:00 a.m. Jan. 7, 2014 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...